DM Clinical Research

Kyle Bramble

In an interview with Life Sciences Review, Mr. Kyle Bramble, Regional Director at DM Clinical Research, discusses the challenges and emerging trends in the world of clinical research and shares his insights into effectively navigating them.

Kyle Bramble is a seasoned clinical research professional with a strong background in pharmaceutical operations, site management and patient engagement. With a foundation in biochemistry and molecular biology, he began his career in bench chemistry before pivoting to clinical research. Over the years, he has held key leadership roles, including Director of Operations and Regional Director at DM Clinical Research, where he led high-performing sites and built scalable growth models.

Career Trajectory: From Molecules to Milestones

My career started in the pharmaceutical industry. Back then, I was deeply immersed in the lab world, working with VWR International, supporting smart labs at GSK, and handling small molecule purification chemistry in their R&D divisions. After earning degrees in biochemistry and molecular biology, I felt a pull toward something more human-facing and more operational. So, I dove straight into benchtop chemistry.

After a couple of years, I began exploring new opportunities and was recruited by a small dermatology center. I joined as a clinical research coordinator, and from the start, it just clicked. I discovered that I had a strong aptitude for the operational aspects of research, including working with patients, managing data, and ensuring the smooth execution of studies. Over the next five years at KGL, I advanced to director of operations and also served as the study manager for both cosmetic and pharmaceutical trials. But growth has a ceiling when you’re standing still, so I stepped out again.

DM Clinical was the next chapter. I started by managing immunology studies as a site director in Philadelphia. Over nearly three years, I helped transform it into one of the company's top-performing locations, consistently supporting other sites, building teams, and eventually taking on struggling centers to bring them up to speed. One such site was in Boston, a location that had experienced several leadership transitions over a short period. I took it over in August, and by April, I was awarded the title of regional director.

But as change doesn't stop, I’m stepping into a new challenge as regional director of client relations at Flourish, moving toward the business development side of life sciences. It’s a natural evolution for where I want to grow next.

Assessing and Navigating the Spanner in the Works

One of the biggest challenges the industry is currently facing stems from shifts in the regulatory landscape under the new administration. These changes are having a noticeable impact on pharmaceutical products and the pipeline of projects set to run.

As a result, there’s increased competition among sites to be selected for study participation. Pharmaceutical companies are becoming much more selective with their investments, carefully evaluating which projects to pursue— and in some cases, even terminating studies prematurely. This has created an environment where site leaders must constantly compete for enrollment performance and factors such as market viability and outreach effectiveness. The heightened scrutiny has led site networks to be more strategic in determining which sites to submit for specific studies. To navigate this environment, we’ve been focused on building more versatile and adaptive site capabilities.

We expanded our capabilities, adding rheumatology and pulmonology studies to compensate for the waning vaccine pipeline. We’ve also prioritized collaboration among our internal medical teams, encouraging cross-functional engagement to improve patient identification and retention. By leveraging shared insights and collective experience across sister sites, we’re creating a more resilient and collaborative network that’s better equipped to meet evolving industry demands.

Leading Along the Curve: Insights from an Industry Leader

Looking ahead, one of the key challenges we anticipate is a potential decline in participant engagement in clinical research, a trend influenced by shifting public sentiment and media narratives.

To address this, leaders should focus on creating meaningful, community-oriented experiences. Hosting on-site events—even those not directly tied to clinical trials—can be a powerful way to build trust and visibility. For example, during my time in dermatology, we held free dermatology exam days where members of the community could come in for skin checks. These types of initiatives foster awareness about the value and purpose of clinical research. When people see the human side of what we do, they’re more likely to participate and stay engaged. At the same time, we need to be mindful of the evolving role of technology in recruitment. The rise of AI-driven tools and robocalling has, in some cases, negatively impacted outreach efforts, as patients may view these tactics as impersonal or intrusive. That is why, maintaining a personal touch becomes even more essential for smaller clinics and standalone sites.

For those navigating this space, the best advice is to remain adaptable. This industry changes overnight. Staying informed, building relationships and embracing flexibility aren’t just survival tactics—they’re how you lead.